Alice K Pau Scott R Penzak Sarita D Boyd Mary McLaughlin Caryn G Morse
10.1002/PHAR.1003
Pharmacotherapy
2012 Jan;32(1):e1-6.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/22392831/
Cyclohexanes / pharmacokinetics End Stage Liver Disease / complications HIV Infections / complications Pyrrolidinones / pharmacokinetics Renal Insufficiency / complications Triazoles / pharmacokinetics
Cyclohexanes / pharmacokinetics End Stage Liver Disease / complications HIV Infections / complications Pyrrolidinones / pharmacokinetics Renal Insufficiency / complications Triazoles / pharmacokinetics Case Reports Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Adult Cyclohexanes / therapeutic use Disease Management End Stage Liver Disease / drug therapy Fatal Outcome HIV Infections / drug therapy Humans Male Maraviroc Metabolic Clearance Rate Pyrrolidinones / therapeutic use Raltegravir Potassium Renal Insufficiency / drug therapy Triazoles / therapeutic use Cyclohexanes Pyrrolidinones Triazoles Raltegravir Potassium Maraviroc
PMC4518450
22392831
Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma
2012